Benefits of Testing for the G12D Mutation of the KRAS Gene in Hepatocellular Carcinoma (HCC) in Senegal

Dia Fatou Kine Sy Thorpe; Thiam Souleymane; Samba Abdourahmane; Soumah Idrissa Yaya; Diedhiou Fatou; Agossou Hortence Honorine Medece; Ka Ibrahima; Deguenonvo Gabriel Nougnignon Comlan; Cisse Fatou; Ndiaye Arame; Coly Najah Fatou; Dial Cherif Mouhamed; Diop Papa Saloum; Diallo Fatou

doi:doi:10.11648/j.ijgg.20261404.12

Research Article |

Benefits of Testing for the G12D Mutation of the KRAS Gene in Hepatocellular Carcinoma (HCC) in Senegal

Dia Fatou Kine Sy Thorpe^*, Thiam Souleymane, Samba Abdourahmane, Soumah Idrissa Yaya, Diedhiou Fatou, Agossou Hortence Honorine Medece, Ka Ibrahima, Deguenonvo Gabriel Nougnignon Comlan, Cisse Fatou, Ndiaye Arame, Coly Najah Fatou, Dial Cherif Mouhamed, Diop Papa Saloum, Diallo Fatou

Published in International Journal of Genetics and Genomics (Volume 14, Issue 4)

Received: 30 September 2026 Accepted: 13 October 2026 Published: 29 October 2026

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Background: The mutation of the KRAS proto-oncogene is frequently detected in various cancers, including hepatocellular carcinoma (HCC). This mutation often results in the failure of treatments based on tyrosine kinase receptor inhibitors. The study's objective was to investigate mutations of codon 12 and 13 of the KRAS gene and assess the risk of developing Hepatocellular Carcinoma. Methods: A prospective, cross-sectional, and analytical study was conducted from November 2018 to October 2021 at the biochemistry and molecular biology laboratory of Cheikh Anta Diop University’s Faculty of Medicine. Mutations of codons 12 and 13 were identified using High Resolution Melting and confirmed by sequencing. Hepatic assessments (transaminases, GGT, PAL, bilirubin, and AFP) were performed on all patients, and histopathological analysis was conducted. Results: The study consisted of 34 patients with an average age of 44±3.4 years and a sex ratio of 5.8. There was a predominance in the age group of 36 to 45 years (38.2%). The prevalence of the G12D mutation of the KRAS gene was 23.5% and was more common in subjects over 45 years (n=5; 11.7%). Hepatic impairments were less pronounced in carriers of the G12D mutation of the KRAS gene, albeit not significantly different. Additionally, tumors of grade 3 and type pT3 appeared more linked to the G12D mutation of the KRAS gene, with prevalences of 18.75% (n=3) and 30.8% (n=4), respectively. The relationship between chronic Hepatitis B Virus carriage and the KRAS gene mutation was not significant. Conclusion: Molecular biology significantly contributes to diagnosis and patient management by identifying molecular markers for pre-therapeutic evaluation.

Published in	International Journal of Genetics and Genomics (Volume 14, Issue 4)
DOI	10.11648/j.ijgg.20261404.12
Page(s)	154-160
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2026. Published by Science Publishing Group

Keywords

Codon 12 and 13 KRAS, HBV, Hepatocellular Carcinoma, Senegal

References

[1]	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021: 71: 209-249. https://doi.org/10.3322/caac.21660
[2]	Ibrahima Diallo et al. Hepatocellular carcinoma in Senegal: epidemiological, clinical and etiological aspects about 229 cases at Hôpital Principal de Dakar. Pan African Medical Journal. 2021; 38(99). https://doi.org/10.11604/pamj.2021.38.99.25195
[3]	N. S. TURHAL, B. SAVAŞ, Ö. ÇOŞKUN, E. BAŞ, B. KARABULUT, D. NART et al. Prevalence of K-Ras mutations in hepatocellular carcinoma: A Turkish Oncology Group pilot study; MOLECULAR AND CLINICAL ONCOLOGY 2015, 3: 1275-1279 https://doi.org/10.3892/mco.2015.633
[4]	E. Tran, P. F. Robbins, Y.‑C. Lu, T. D. Prickett, J. J. Gartner, Li Jia et al. T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer, the new england journal of medicine 2016, 375; 23 https://doi.org/10.1056/NEJMoa1609279
[5]	Allaire M, Nault JC. Génétics of hépatocellular carcinoma. La lettre de l’hépato-gasro-entérologue 2017; 20(1): 18-23.
[6]	R. A-DAMMAK, A. SAADALLAH-KALLEL, I. MILADI-ABDENNADHER, A. KHABIR, T. SALLEMI-BOUDAWARA, R. MOKDAD-GARGOURI. et al. Mutations du genekras chez les patients du sud tunisien atteint de cancer colorectal: signification clinique. J. I. M. Sfax, 2015 N° 21/ 22: 39-44
[7]	Thiam S, Dia F. K. ST., Sambiani D. M., Diop PS, Ka I., Deguenonvo G. N. et al. KRAS and BRAF Mutations in Patients with Hepatocellular Carcinoma in Senegal: international Journal of Genetics and Genomics. 2022; 10(1): 37-42 https://doi.org/10.11648/j.ijgg.20221001.16
[8]	S. Diallo, M. L. Bassène, M. N. Gueye, M. A. Thioubou, D. Dia, M. Mbengue et al. Viral Hepatitis B : clinical,paraclinical and progressive aspects in the Hepato-gastroenterology Departement at the Aristide Le Dantec Hospital :about 728 cases.Pan African Medical Journal. 2018; 31: 82 https://doi.org/10.11604/pamj.2018.31.82.14725
[9]	M. Ranaivomanana, A. Rakotovao, R. Fanantenantsoa, D Randrianiaina, H. S. Razafimahefa, F. Rafaramino. Preliminary epidemioclinical study of hepatocellular carcinomas observed at University Hospital Center Tambohobe, Fianarantsoa, Rev. méd. Madag. 2017; 7(1): 779 - 782 https://doi.org/10.62606/RMMao00192
[10]	Sasaki M, Sato Y, Nakanuma Y. Mutational landscape of combined hepatocellular carcinoma and cholangiocarcinoma, and its clinicopathological significance. Histopathology. 2017; 70(3): 423-34. https://doi.org/10.1111/his.13084
[11]	Chaitanya R. Churi, Rachna Shroff, Ying Wang, Asif Rashid, HyunSeon C. Kang, Jacqueline Weatherly et al. (2014) Mutation Profiling in Cholangiocarcinoma: Prognostic and Therapeutic Implications. PLoS one 9(12): e115383. https://doi.org/10.1371/journal.pone.0115383
[12]	Joseph NM, Tsokos CG, Umetsu SE, Shain AH, Kelley RK, Onodera C, et al. Genomic profiling of combined hepatocellular-cholangiocarcinoma reveals similar genetics to hepatocellular carcinoma. J Pathol. 2019; 248(2): 164-178. https://doi.org/10.1002/path.5243
[13]	Hung H. Treatment modalities for hepatocellular carcinoma. Curr Cancer Drug Targets. 2005; 5(2): 131–8. https://doi.org/10.2174/1568009053202063
[14]	Sehonou J, Dodo LRS, Azon-Kouanou A, Agbodande KA, Zannou DM, Houngbe F. Epidemiological and diagnostic profile of hepatocellular carcinoma in the internal medicine departement of the CNHU-HKM of Cotonou. J Soc Biol Clin Bénin. 2017; 27: 47-51.
[15]	Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut. 2014; 63(5): 844–55. https://doi.org/10.1136/gutjnl-2013-306627
[16]	Cheng Z, He L, Guo Y, Song Y, Song S, Zhang L. The combination therapy of transarterial chemoembolisation and sorafenib is the preferred palliative treatment for advanced hepatocellular carcinoma patients: a meta-analysis. World J Surg Oncol. 2020; 18(1): 243. https://doi.org/10.1186/s12957-020-02017-0
[17]	Bekondi C, Mobima T, Ouavènè JO, Koffi B, Konamna X, Béré A, et al. Étiopathology of hépatocellular carcinoma in Bangui, Central African Républic : clinical,biological charactéristics and virological aspects of patients. Pathol Biol (Paris). 2010; 58(2): 152-5. https://doi.org/10.1016/j.patbio.2009.07.027
[18]	Pratic F, Ouarrach H, Samlani-Sebbane Z, Oubaha S, Krati K. hepatocellular carcinoma :epidemiological,clinical and therapeutic profile at Marrakech University Hospital (about 76 cases ). Hegel. 2017; 7(3): 195-200. https://doi.org/10.3917/heg.073.0195
[19]	Harir N, Zeggai S, Tou A, Yekoru DJ. Hepatocellular carcinoma in western Algeria : epidemiological and clinicopathological profile. Rev Med Madag.2016; 6(1): 681-685.
[20]	Robert L, Bazin C, Ayav A, Marchal F, Bresler L, Régent D. Predictive Factors of local failure of radiofrequency treatment of liver lesions.J Radiol. 2009; 90(10): 1425. https://doi.org/10.1016/S0221-0363(09)75617-3
[21]	K. Wakizaka., H. Yokoo, T. Kamiyama, M. Ohira, KoichiKato, Y. Fujii et al. Clinical and pathological features of combined hepatocellular cholangiocarcinoma compared with other liver cancers. Journal of GastroenterologyandHepatology2019; 34(6): 1074–80 https://doi.org/10.1111/jgh.14547

Cite This Article

Plain Text BibTeX RIS

APA Style

Thorpe, D. F. K. S., Souleymane, T., Abdourahmane, S., Yaya, S. I., Fatou, D., et al. (2026). Benefits of Testing for the G12D Mutation of the KRAS Gene in Hepatocellular Carcinoma (HCC) in Senegal. International Journal of Genetics and Genomics, 14(4), 154-160. https://doi.org/10.11648/j.ijgg.20261404.12

Copy | Download

ACS Style

Thorpe, D. F. K. S.; Souleymane, T.; Abdourahmane, S.; Yaya, S. I.; Fatou, D., et al. Benefits of Testing for the G12D Mutation of the KRAS Gene in Hepatocellular Carcinoma (HCC) in Senegal. Int. J. Genet. Genomics 2026, 14(4), 154-160. doi: 10.11648/j.ijgg.20261404.12

Copy | Download

AMA Style

Thorpe DFKS, Souleymane T, Abdourahmane S, Yaya SI, Fatou D, et al. Benefits of Testing for the G12D Mutation of the KRAS Gene in Hepatocellular Carcinoma (HCC) in Senegal. Int J Genet Genomics. 2026;14(4):154-160. doi: 10.11648/j.ijgg.20261404.12

Copy | Download

@article{10.11648/j.ijgg.20261404.12,
  author = {Dia Fatou Kine Sy Thorpe and Thiam Souleymane and Samba Abdourahmane and Soumah Idrissa Yaya and Diedhiou Fatou and Agossou Hortence Honorine Medece and Ka Ibrahima and Deguenonvo Gabriel Nougnignon Comlan and Cisse Fatou and Ndiaye Arame and Coly Najah Fatou and Dial Cherif Mouhamed and Diop Papa Saloum and Diallo Fatou},
  title = {Benefits of Testing for the G12D Mutation of the KRAS Gene in Hepatocellular Carcinoma (HCC) in Senegal},
  journal = {International Journal of Genetics and Genomics},
  volume = {14},
  number = {4},
  pages = {154-160},
  doi = {10.11648/j.ijgg.20261404.12},
  url = {https://doi.org/10.11648/j.ijgg.20261404.12},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijgg.20261404.12},
  abstract = {Background: The mutation of the KRAS proto-oncogene is frequently detected in various cancers, including hepatocellular carcinoma (HCC). This mutation often results in the failure of treatments based on tyrosine kinase receptor inhibitors. The study's objective was to investigate mutations of codon 12 and 13 of the KRAS gene and assess the risk of developing Hepatocellular Carcinoma. Methods: A prospective, cross-sectional, and analytical study was conducted from November 2018 to October 2021 at the biochemistry and molecular biology laboratory of Cheikh Anta Diop University’s Faculty of Medicine. Mutations of codons 12 and 13 were identified using High Resolution Melting and confirmed by sequencing. Hepatic assessments (transaminases, GGT, PAL, bilirubin, and AFP) were performed on all patients, and histopathological analysis was conducted. Results: The study consisted of 34 patients with an average age of 44±3.4 years and a sex ratio of 5.8. There was a predominance in the age group of 36 to 45 years (38.2%). The prevalence of the G12D mutation of the KRAS gene was 23.5% and was more common in subjects over 45 years (n=5; 11.7%). Hepatic impairments were less pronounced in carriers of the G12D mutation of the KRAS gene, albeit not significantly different. Additionally, tumors of grade 3 and type pT3 appeared more linked to the G12D mutation of the KRAS gene, with prevalences of 18.75% (n=3) and 30.8% (n=4), respectively. The relationship between chronic Hepatitis B Virus carriage and the KRAS gene mutation was not significant. Conclusion: Molecular biology significantly contributes to diagnosis and patient management by identifying molecular markers for pre-therapeutic evaluation.},
 year = {2026}
}

Copy | Download

TY  - JOUR
T1  - Benefits of Testing for the G12D Mutation of the KRAS Gene in Hepatocellular Carcinoma (HCC) in Senegal
AU  - Dia Fatou Kine Sy Thorpe
AU  - Thiam Souleymane
AU  - Samba Abdourahmane
AU  - Soumah Idrissa Yaya
AU  - Diedhiou Fatou
AU  - Agossou Hortence Honorine Medece
AU  - Ka Ibrahima
AU  - Deguenonvo Gabriel Nougnignon Comlan
AU  - Cisse Fatou
AU  - Ndiaye Arame
AU  - Coly Najah Fatou
AU  - Dial Cherif Mouhamed
AU  - Diop Papa Saloum
AU  - Diallo Fatou
Y1  - 2026/10/29
PY  - 2026
N1  - https://doi.org/10.11648/j.ijgg.20261404.12
DO  - 10.11648/j.ijgg.20261404.12
T2  - International Journal of Genetics and Genomics
JF  - International Journal of Genetics and Genomics
JO  - International Journal of Genetics and Genomics
SP  - 154
EP  - 160
PB  - Science Publishing Group
SN  - 2376-7359
UR  - https://doi.org/10.11648/j.ijgg.20261404.12
AB  - Background: The mutation of the KRAS proto-oncogene is frequently detected in various cancers, including hepatocellular carcinoma (HCC). This mutation often results in the failure of treatments based on tyrosine kinase receptor inhibitors. The study's objective was to investigate mutations of codon 12 and 13 of the KRAS gene and assess the risk of developing Hepatocellular Carcinoma. Methods: A prospective, cross-sectional, and analytical study was conducted from November 2018 to October 2021 at the biochemistry and molecular biology laboratory of Cheikh Anta Diop University’s Faculty of Medicine. Mutations of codons 12 and 13 were identified using High Resolution Melting and confirmed by sequencing. Hepatic assessments (transaminases, GGT, PAL, bilirubin, and AFP) were performed on all patients, and histopathological analysis was conducted. Results: The study consisted of 34 patients with an average age of 44±3.4 years and a sex ratio of 5.8. There was a predominance in the age group of 36 to 45 years (38.2%). The prevalence of the G12D mutation of the KRAS gene was 23.5% and was more common in subjects over 45 years (n=5; 11.7%). Hepatic impairments were less pronounced in carriers of the G12D mutation of the KRAS gene, albeit not significantly different. Additionally, tumors of grade 3 and type pT3 appeared more linked to the G12D mutation of the KRAS gene, with prevalences of 18.75% (n=3) and 30.8% (n=4), respectively. The relationship between chronic Hepatitis B Virus carriage and the KRAS gene mutation was not significant. Conclusion: Molecular biology significantly contributes to diagnosis and patient management by identifying molecular markers for pre-therapeutic evaluation.
VL  - 14
IS  - 4
ER  -

Copy | Download

Author Information

Dia Fatou Kine Sy Thorpe

Laboratory of Biochemistry and Molecular Biology, Cheikh Anta Diop University, Dakar, Senegal

Contact Email
Thiam Souleymane

Laboratory of Biochemistry and Molecular Biology, Cheikh Anta Diop University, Dakar, Senegal;Laboratory of Biochemistry, Dalal Jamm Hospital, Dakar, Senegal
Samba Abdourahmane

Laboratory of Biochemistry and Molecular Biology, Cheikh Anta Diop University, Dakar, Senegal;Laboratory of Biochemistry, Aristide Le Dantec Hospital, Dakar, Senegal
Soumah Idrissa Yaya

Laboratory of Biochemistry and Molecular Biology, Cheikh Anta Diop University, Dakar, Senegal
Diedhiou Fatou

Laboratory of Biochemistry and Molecular Biology, Cheikh Anta Diop University, Dakar, Senegal
Agossou Hortence Honorine Medece

Laboratory of Biochemistry and Molecular Biology, Cheikh Anta Diop University, Dakar, Senegal
Ka Ibrahima

Surgical Department, General Hospital of Grand Yoff, Dakar, Senegal
Deguenonvo Gabriel Nougnignon Comlan

Cytology and Pathology Department, General Hospital of Grand Yoff, Dakar, Senegal
Cisse Fatou

Laboratory of Biochemistry and Molecular Biology, Cheikh Anta Diop University, Dakar, Senegal;Laboratory of Biochemistry, Dalal Jamm Hospital, Dakar, Senegal
Ndiaye Arame

Laboratory of Biochemistry and Molecular Biology, Cheikh Anta Diop University, Dakar, Senegal;Laboratory of Biochemistry, Aristide Le Dantec Hospital, Dakar, Senegal
Coly Najah Fatou

Department of Medical Biology and Functional Exploration(Pharmaceutical Biochemistry), Thies University, Thies, Senegal
Dial Cherif Mouhamed

Cytology and Pathology Department, General Hospital of Grand Yoff, Dakar, Senegal
Diop Papa Saloum

Surgical Department, General Hospital of Grand Yoff, Dakar, Senegal
Diallo Fatou

Laboratory of Biochemistry and Molecular Biology, Cheikh Anta Diop University, Dakar, Senegal;Laboratory of Biochemistry, Aristide Le Dantec Hospital, Dakar, Senegal

Download PDF

Submit an Article

Sections

Plain Text BibTeX RIS

APA Style

Thorpe, D. F. K. S., Souleymane, T., Abdourahmane, S., Yaya, S. I., Fatou, D., et al. (2026). Benefits of Testing for the G12D Mutation of the KRAS Gene in Hepatocellular Carcinoma (HCC) in Senegal. International Journal of Genetics and Genomics, 14(4), 154-160. https://doi.org/10.11648/j.ijgg.20261404.12

Copy | Download

ACS Style

Thorpe, D. F. K. S.; Souleymane, T.; Abdourahmane, S.; Yaya, S. I.; Fatou, D., et al. Benefits of Testing for the G12D Mutation of the KRAS Gene in Hepatocellular Carcinoma (HCC) in Senegal. Int. J. Genet. Genomics 2026, 14(4), 154-160. doi: 10.11648/j.ijgg.20261404.12

Copy | Download

AMA Style

Thorpe DFKS, Souleymane T, Abdourahmane S, Yaya SI, Fatou D, et al. Benefits of Testing for the G12D Mutation of the KRAS Gene in Hepatocellular Carcinoma (HCC) in Senegal. Int J Genet Genomics. 2026;14(4):154-160. doi: 10.11648/j.ijgg.20261404.12

Copy | Download

@article{10.11648/j.ijgg.20261404.12,
  author = {Dia Fatou Kine Sy Thorpe and Thiam Souleymane and Samba Abdourahmane and Soumah Idrissa Yaya and Diedhiou Fatou and Agossou Hortence Honorine Medece and Ka Ibrahima and Deguenonvo Gabriel Nougnignon Comlan and Cisse Fatou and Ndiaye Arame and Coly Najah Fatou and Dial Cherif Mouhamed and Diop Papa Saloum and Diallo Fatou},
  title = {Benefits of Testing for the G12D Mutation of the KRAS Gene in Hepatocellular Carcinoma (HCC) in Senegal},
  journal = {International Journal of Genetics and Genomics},
  volume = {14},
  number = {4},
  pages = {154-160},
  doi = {10.11648/j.ijgg.20261404.12},
  url = {https://doi.org/10.11648/j.ijgg.20261404.12},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijgg.20261404.12},
  abstract = {Background: The mutation of the KRAS proto-oncogene is frequently detected in various cancers, including hepatocellular carcinoma (HCC). This mutation often results in the failure of treatments based on tyrosine kinase receptor inhibitors. The study's objective was to investigate mutations of codon 12 and 13 of the KRAS gene and assess the risk of developing Hepatocellular Carcinoma. Methods: A prospective, cross-sectional, and analytical study was conducted from November 2018 to October 2021 at the biochemistry and molecular biology laboratory of Cheikh Anta Diop University’s Faculty of Medicine. Mutations of codons 12 and 13 were identified using High Resolution Melting and confirmed by sequencing. Hepatic assessments (transaminases, GGT, PAL, bilirubin, and AFP) were performed on all patients, and histopathological analysis was conducted. Results: The study consisted of 34 patients with an average age of 44±3.4 years and a sex ratio of 5.8. There was a predominance in the age group of 36 to 45 years (38.2%). The prevalence of the G12D mutation of the KRAS gene was 23.5% and was more common in subjects over 45 years (n=5; 11.7%). Hepatic impairments were less pronounced in carriers of the G12D mutation of the KRAS gene, albeit not significantly different. Additionally, tumors of grade 3 and type pT3 appeared more linked to the G12D mutation of the KRAS gene, with prevalences of 18.75% (n=3) and 30.8% (n=4), respectively. The relationship between chronic Hepatitis B Virus carriage and the KRAS gene mutation was not significant. Conclusion: Molecular biology significantly contributes to diagnosis and patient management by identifying molecular markers for pre-therapeutic evaluation.},
 year = {2026}
}

Copy | Download

TY  - JOUR
T1  - Benefits of Testing for the G12D Mutation of the KRAS Gene in Hepatocellular Carcinoma (HCC) in Senegal
AU  - Dia Fatou Kine Sy Thorpe
AU  - Thiam Souleymane
AU  - Samba Abdourahmane
AU  - Soumah Idrissa Yaya
AU  - Diedhiou Fatou
AU  - Agossou Hortence Honorine Medece
AU  - Ka Ibrahima
AU  - Deguenonvo Gabriel Nougnignon Comlan
AU  - Cisse Fatou
AU  - Ndiaye Arame
AU  - Coly Najah Fatou
AU  - Dial Cherif Mouhamed
AU  - Diop Papa Saloum
AU  - Diallo Fatou
Y1  - 2026/10/29
PY  - 2026
N1  - https://doi.org/10.11648/j.ijgg.20261404.12
DO  - 10.11648/j.ijgg.20261404.12
T2  - International Journal of Genetics and Genomics
JF  - International Journal of Genetics and Genomics
JO  - International Journal of Genetics and Genomics
SP  - 154
EP  - 160
PB  - Science Publishing Group
SN  - 2376-7359
UR  - https://doi.org/10.11648/j.ijgg.20261404.12
AB  - Background: The mutation of the KRAS proto-oncogene is frequently detected in various cancers, including hepatocellular carcinoma (HCC). This mutation often results in the failure of treatments based on tyrosine kinase receptor inhibitors. The study's objective was to investigate mutations of codon 12 and 13 of the KRAS gene and assess the risk of developing Hepatocellular Carcinoma. Methods: A prospective, cross-sectional, and analytical study was conducted from November 2018 to October 2021 at the biochemistry and molecular biology laboratory of Cheikh Anta Diop University’s Faculty of Medicine. Mutations of codons 12 and 13 were identified using High Resolution Melting and confirmed by sequencing. Hepatic assessments (transaminases, GGT, PAL, bilirubin, and AFP) were performed on all patients, and histopathological analysis was conducted. Results: The study consisted of 34 patients with an average age of 44±3.4 years and a sex ratio of 5.8. There was a predominance in the age group of 36 to 45 years (38.2%). The prevalence of the G12D mutation of the KRAS gene was 23.5% and was more common in subjects over 45 years (n=5; 11.7%). Hepatic impairments were less pronounced in carriers of the G12D mutation of the KRAS gene, albeit not significantly different. Additionally, tumors of grade 3 and type pT3 appeared more linked to the G12D mutation of the KRAS gene, with prevalences of 18.75% (n=3) and 30.8% (n=4), respectively. The relationship between chronic Hepatitis B Virus carriage and the KRAS gene mutation was not significant. Conclusion: Molecular biology significantly contributes to diagnosis and patient management by identifying molecular markers for pre-therapeutic evaluation.
VL  - 14
IS  - 4
ER  -

Copy | Download